Akela Pharma Inc. Announces Amendments to its Original Licensing and Development Agreement With Janssen Pharmaceutica N.V.

MONTREAL, June 9 /CNW Telbec/ - Akela Pharma Inc. (TSX: "AKL"), a drug development company focused on developing therapies for the inhalation and pain markets, today announced amendments to its original licensing and development agreement with Janssen Pharmaceutica NV for Fentanyl TAIFUN(R), its fast-acting Fentanyl formulation using the company's TAIFUN(R) dry powder inhaler for the treatment of breakthrough cancer pain.